STOCK TITAN
  1. Home
  2. Sec-filings
  3. ATNM
  4. [Form 4] Actinium Pharmaceuticals, Inc. Insider Trading Activity

Actinium grants CEO 1.13M options at $1.00

Actinium Pharmaceuticals’ CEO received large option and RSU grants with multi‑year vesting on September 2, 2026.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Actinium Pharmaceuticals, Inc. (ATNM) reported that Chief Executive Officer and director Sandesh Seth received significant equity awards on September 2, 2026. He was granted stock options to acquire 1,130,400 shares of common stock at an exercise price of $1.00 per share, vesting in fifty equal monthly tranches and expiring on September 2, 2036. He also received 753,600 restricted stock units that vest in three equal annual installments and 1,027,274 restricted stock units that vest fully on the third anniversary of the grant date. No Rule 10b5-1 trading plan is reported for these awards.

Positive

  • None.

Negative

  • None.
Insider SETH SANDESH
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F3 1,130,400 $0.00 $0.00
Grant/Award Common Stock F1 753,600 $0.00 $0.00
Grant/Award Common Stock F2 1,027,274 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 1,130,400 contracts (Direct); Common Stock — 1,965,355 shares (Direct)
Footnotes (3)
  1. F1. Represents a grant of restricted stock units ("RSUs"). These RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant.
  2. F2. Represents a grant of RSUs. These RSUs vest fully on the third anniversary of the date of grant.
  3. F3. The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant.
Stock options granted 1,130,400 options Grant to CEO on September 2, 2026
Option exercise price $1.00 per share Exercise price for 1,130,400 options granted September 2, 2026
Option expiration date September 2, 2036 Expiration of options granted to CEO
RSUs with graded vesting 753,600 RSUs Vest 1/3 each year on first, second, and third anniversaries of grant
RSUs with cliff vesting 1,027,274 RSUs Vest fully on third anniversary of grant date
Options held after transaction 1,130,400 options CEO’s total reported option holdings following this grant
restricted stock units ("RSUs") financial
"Represents a grant of restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
stock options financial
"The stock options vest and become exercisable in fifty equal monthly"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
vest financial
"These RSUs vest as follows: 1/3 on the first anniversary"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

What equity awards did ATNM grant to its CEO on September 2, 2026?
Actinium Pharmaceuticals granted CEO Sandesh Seth 1,130,400 stock options at a $1.00 exercise price, plus 753,600 RSUs with three-year graded vesting and 1,027,274 RSUs that vest fully on the third anniversary of the grant.

What are the terms of the new stock options granted by ATNM to the CEO?
The CEO received options for 1,130,400 shares of Actinium common stock at an exercise price of $1.00 per share. These options vest in fifty equal monthly tranches starting on the grant date and expire on September 2, 2036.

How do the 753,600 ATNM RSUs granted to the CEO vest?
The 753,600 restricted stock units granted to the CEO vest over three years: 1/3 on the first anniversary, 1/3 on the second anniversary, and 1/3 on the third anniversary of the September 2, 2026 grant date.

What is the vesting schedule for the 1,027,274 ATNM RSUs granted to the CEO?
The 1,027,274 RSUs granted to the CEO vest fully on the third anniversary of the September 2, 2026 grant date. Until vesting, they remain unearned and are subject to the award terms.

Were the ATNM CEO’s September 2026 equity grants under a Rule 10b5-1 plan?
No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with the CEO’s September 2, 2026 option and RSU grants.

How many options does the ATNM CEO hold after this grant?
After the September 2, 2026 grant, the CEO holds 1,130,400 stock options as reported in the filing, representing his option position following this specific transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SETH SANDESH
(Last)(First)(Middle)
C/O ACTINIUM PHARMACEUTICALS, INC.
100 PARK AVE., 23RD FLOOR
(Street)
NEW YORK NEW YORK 10017
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Actinium Pharmaceuticals, Inc. [ ATNM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/02/2026A753,600(1)A$0938,081D
Common Stock09/02/2026A1,027,274(2)A$01,965,355D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$109/02/2026A1,130,400 (3)09/02/2036Common Stock1,130,400$01,130,400D
Explanation of Responses:
1. Represents a grant of restricted stock units ("RSUs"). These RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant.
2. Represents a grant of RSUs. These RSUs vest fully on the third anniversary of the date of grant.
3. The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant.
/s/ Sandesh Seth09/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR